Literature DB >> 24446254

Alterations of oxidative phosphorylation complexes in astrocytomas.

René Günther Feichtinger1, Serge Weis, Johannes Adalbert Mayr, Franz Zimmermann, Reinhard Geilberger, Wolfgang Sperl, Barbara Kofler.   

Abstract

The shift in cellular energy production from oxidative phosphorylation (OXPHOS) to glycolysis, even under aerobic conditions, called the Warburg effect, is a feature of most solid tumors. The activity levels of OXPHOS complexes and citrate synthase were determined in astrocytomas. A gradual decrease of citrate synthase and OXPHOS complexes was observed depending on tumor grade. In low-grade astrocytomas (WHO grade II), enzyme activities of citrate synthase, complex I, and complex V were comparable to those of normal brain tissue. A trend to reduced activities was observed for complexes II-IV. In glioblastoma (WHO grade IV), activities of citrate synthase and complexes I-IV were decreased by 56-92% as compared with normal brain. Immunohistochemical staining for porin revealed that the tumorpil of low-grade astrocytomas displays characteristics of the mitochondria-rich neuropil of normal brain tissue. In high-grade tumors (WHO grades III and IV), the tumorpil was characterized by severe morphologic alterations as well as loss of "pilem" structures. Specific alterations of OXPHOS complexes were observed in all astrocytic tumors by immunohistochemical analysis: 80% of astrocytomas exhibited severe deficiency of complex IV; complex I showed a gradual reduction in amount with increasing tumor grade, whereas complex II showed reduced levels only in high-grade (WHO grade IV) tumors (9/12); complexes III and V did not show significant alterations compared with normal brain tissue. OXPHOS defects were present not only in the cell bodies of tumor cells but also in the pilem structures, indicating that the ramifications/protuberances (tumorpil) in general originate from tumor cells.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  OXPHOS defect; Warburg effect; mitochondria; neuropil

Mesh:

Substances:

Year:  2014        PMID: 24446254     DOI: 10.1002/glia.22621

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  37 in total

1.  Commentary on "Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme".

Authors:  Colin E Champ; Rainer J Klement
Journal:  Strahlenther Onkol       Date:  2015-03       Impact factor: 3.621

2.  Previously Unreported Biallelic Mutation in DNAJC19: Are Sensorineural Hearing Loss and Basal Ganglia Lesions Additional Features of Dilated Cardiomyopathy and Ataxia (DCMA) Syndrome?

Authors:  Sema Kalkan Ucar; Johannes A Mayr; René G Feichtinger; Ebru Canda; Mahmut Çoker; Saskia B Wortmann
Journal:  JIMD Rep       Date:  2016-12-08

3.  Mitochondrial energy metabolism and signalling in human glioblastoma cell lines with different PTEN gene status.

Authors:  Marina Comelli; Ivan Pretis; Alessia Buso; Irene Mavelli
Journal:  J Bioenerg Biomembr       Date:  2017-12-06       Impact factor: 2.945

4.  Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Authors:  Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee
Journal:  Neurochem Res       Date:  2019-04-25       Impact factor: 3.996

5.  Alterations of oxidative phosphorylation in meningiomas and peripheral nerve sheath tumors.

Authors:  René G Feichtinger; Serge Weis; Johannes A Mayr; Franz A Zimmermann; Barbara Bogner; Wolfgang Sperl; Barbara Kofler
Journal:  Neuro Oncol       Date:  2015-06-23       Impact factor: 12.300

6.  Atypical Clinical Presentations of TAZ Mutations: An Underdiagnosed Cause of Growth Retardation?

Authors:  Charlotte Thiels; Martin Fleger; Martina Huemer; Richard J Rodenburg; Frederic M Vaz; Riekelt H Houtkooper; Tobias B Haack; Holger Prokisch; René G Feichtinger; Thomas Lücke; Johannes A Mayr; Saskia B Wortmann
Journal:  JIMD Rep       Date:  2016-01-03

Review 7.  Energy metabolism in neuroblastoma and Wilms tumor.

Authors:  Sepideh Aminzadeh; Silvia Vidali; Wolfgang Sperl; Barbara Kofler; René G Feichtinger
Journal:  Transl Pediatr       Date:  2015-01

8.  VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.

Authors:  Tasleem Arif; Yakov Krelin; Itay Nakdimon; Daniel Benharroch; Avijit Paul; Daniela Dadon-Klein; Varda Shoshan-Barmatz
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

9.  Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to FBXL4 mutations.

Authors:  Martina Huemer; Daniela Karall; Anna Schossig; Jose E Abdenur; Fatma Al Jasmi; Caroline Biagosch; Felix Distelmaier; Peter Freisinger; Brett H Graham; Tobias B Haack; Natalie Hauser; Jozef Hertecant; Darius Ebrahimi-Fakhari; Vassiliki Konstantopoulou; Karen Leydiker; Charles M Lourenco; Sabine Scholl-Bürgi; Ekkehard Wilichowski; Nicole I Wolf; Saskia B Wortmann; Robert W Taylor; Johannes A Mayr; Penelope E Bonnen; Wolfgang Sperl; Holger Prokisch; Robert McFarland
Journal:  J Inherit Metab Dis       Date:  2015-04-14       Impact factor: 4.982

Review 10.  Mitochondrial Inhibition: a Treatment Strategy in Cancer?

Authors:  Maria J Bueno; Jose L Ruiz-Sepulveda; Miguel Quintela-Fandino
Journal:  Curr Oncol Rep       Date:  2021-03-17       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.